Other
JAK inhibitors
Janus associated kinase (JAK) inhibitor (non-biologic)
Other names: tofacitinib, Xeljanz, upadacitinib, Rinvoq, baricitinib, Olumiant
Wait
2 weeks
ground trial when starting
Other FAA documents add more.
Examiner
The examiner can issue when the document's criteria are met
FAA label
ACCEPTABLE
The FAA's biologics sheet lists the kinase inhibitors baricitinib, tofacitinib and upadacitinib as acceptable monotherapy medication when the underlying condition qualifies, with a two-week ground trial when starting and no no-fly time after later doses, warning about cardiovascular events and blood clots.
Track your medicationsCompare FAA documents: JAK inhibitorsWhat each of the two FAA documents says, in plain wordsOpen
Wait
- no wait after later doses
The FAA's CACI – Arthritis Worksheet lists them (JAK) among its acceptable medications as any single medication after a 2-week ground trial, with no post-dose observation time, and says the examiner can issue if the pilot meets all of its acceptable certification criteria.
- 14 days after starting: ground observation
Show the FAA's words: JAK inhibitorsThe official FAA wording: two passages, each with its document and dateOpen
Initial observation: All require a 2-week no-fly/ground trial to verify no side effects.
ACCEPTABLE BIOLOGICS - MONOTHERAPY MEDICATION Permitted if the underlying condition qualifies; consult the condition pages for details.
Non-Biologic Medications Post-dose Observation No-Fly times. Kinase Inhibitor: baricitinib (Olumiant), tofacitinib (Xeljanz), upadacitinib (Rinvoq). Warn for cardiovascular events and blood clots (VTE) for all, None
If the applicant meets ALL the acceptable certification criteria listed below, the AME can issue
Janus Associated Kinase Inhibitor (JAK)
Any singe medication listed below after a 2-week ground trial and:
No post-dose observation time:
JAK: baricitinib (Olumiant); tofacitinib (Xeljanz); upadacitinib (Rinvoq)